HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carrasquillo, J. A. Articles by Larson, S. M. Search for Related Content PubMed PubMed Citation Articles by Carrasquillo, J. A. Articles by Larson, S. M.

Effect of Antibody Dose on the Imaging and Biodistribution of Indium-111 9.2.27 Anti-Melanoma Monoclonal Antibody

Nuclear Medicine Department, Clinical Center, National Institutes of Health, Bethesda
Biological Therapy Branch, Biologic Response Modifiers Program, National Cancer Institute, Frederick, Maryland

Correspondence: For reprints contact: Jorge A. Carrasquillo, MD, Bldg. 10 Room 1C401, Nuclear Medicine Dept., National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892.

ABSTRACT

Eleven patients with metastatic melanoma underwent serial gamma camera imaging and biodistribution measurements after i.v. injection of escalating doses of [¹¹¹In]9.2.27, an anti-melanoma murine monoclonal antibody. Patients received a fixed dose of 1 mg of [¹¹¹In] 9.2.27, with no additional 9.2.27 (five patients), or co-infused with 49 mg (five patients) or 99 mg (one patient) of unlabeled, unconjugated 9.2.27. Higher doses resulted in prolonged blood-pool retention, less uptake in spleen and bone marrow, and appeared to have a positive effect in improving tumor imaging. A dose of 1 mg of 9.2.27 permitted detection of tumors in two of five patients and two of ten lesions, while with 50 mg, tumors were detected in all patients and in 24 of 32 lesions. Human gamma globulin injected prior to administration of [¹¹¹In]9.2.27 failed to block the prominent liver, spleen, and bone marrow uptake. No toxicity was observed. These results indicate the feasibility of imaging metastatic melanoma with [¹¹¹In]9.2.27 and suggest that antibody dose may be a critical determinant of biodistribution and tumor uptake.

This article has been cited by other articles:

				J. Chen, Z. Cheng, T. J. Hoffman, S. S. Jurisson, and T. P. Quinn Melanoma-targeting Properties of 99mTechnetium-labeled Cyclic {{alpha}}-Melanocyte-stimulating Hormone Peptide Analogues Cancer Res., October 1, 2000; 60(20): 5649 - 5658. [Abstract] [Full Text]